We are delighted to welcome three new experts to our Grant Review and Monitoring committee. The committee assesses and makes recommendations on which projects to fund, and monitors progress on current projects. Professor Martin van den Bent and Professor Martin Taphoorn join us from Erasmus University and the Hague Medical Centre, both in the Netherlands, and Professor Chris Twelves from the University of Leeds. All three new GRAM members are leaders in their fields with impressive biographies and extensive relevant experience – read more about them below. This follows the retirement from GRAM of Professor Jillian Birch from the University of Leeds and forthcoming end of term of office of Dr Stephen Falk of Bristol Oncology centre later this year. A big thank you to Professor Birch, Dr Falk and all our GRAM members for their work – we could not do it without you!
Professor Martin Taphoorn
Professor Martin Taphoorn has combined clinical work in The Hague with a professorship in neuro-oncology at the VU University Medical Center Amsterdam since 2007.
He is an active member of both the EORTC Brain Tumour Group and Quality of Life Group.
His research concentrates on quality of life and palliative care for brain tumour patients.
Professor Chris Twelves
Professor Chris Twelves is Professor of Clinical Cancer Pharmacology and Oncology, & Head, Clinical Cancer Research Groups, Leeds Institute of Molecular Medicine and St James’s Institute of Oncology
He Chaired the New Drug Development Group of the EORTC and has sat on the Feasibility Studies Committee and New Agents Committee of Cancer Research UK.
Professor Twelves is a medical oncologist with a particular interest in new drug development and clinical pharmacology; his clinical practice has been in colorectal and breast cancer.
Find out more about Professor Twelves on the University of Leeds and Institute of Cancer Therapeutics websites.
Professor Martin van den Bent
Professor Martin van den Bent works as a Consultant Neurologist and Professor of Neuro-oncology at the Daniel den Hoed Cancer Center and Erasmus University Hospital, Rotterdam, The Netherlands.
He is past chair of the EORTC Brain Tumour Group and has been a member of the SDBTT Scientific and Medical Advisory Board for several years.
His research interests include brain tumour clinical trials, prognostic markers in neurooncology and the genetic changes that occur in brain tumours.
